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Abstract
Background: Dementia networks in Germany constitute a specialised setting for integrated dementia care and
have shown benefits on relevant outcomes, including those of drug treatment. National guidelines recommend
treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate
antagonist (memantine) to reduce cognitive symptoms. However, prescription rates are lower than 30 % in general
practises. This study aims to describe antidementia drug treatment and the factors that are associated with the
treatment in different dementia networks across Germany.
Methods: We have analysed the socio-demographic, clinical and utilisation data from 560 patients with dementia
(PWD), as well as data from their caregivers, in 13 selected dementia networks in Germany. The patients and caregivers
were interviewed in their homes or in the network facilities. Multiple logistic regression models were fitted to evaluate the
socio-demographic and clinical factors associated with the utilisation of antidementia drug treatment in the
various networks.
Results: In all of the networks in the study, 52 % of the participants received an antidementia drug treatment.
Factors associated with the utilisation of the antidementia drug treatment were: formal diagnosis (OR = 16.81,
p < 0.001), association with a physician in the network (OR = 3.69, p < 0.001), higher number of comorbidities
(OR = 0.88, p = 0.039), living alone (OR = 0.51, p = 0.032) and higher age (OR = 2.97, p = 0.002).
Conclusion: Medical treatment of PWD with antidementia drugs in dementia networks in Germany is more
frequent than in primary and nursing home care settings. Our findings also suggest that participants with a
formal diagnosis and a physician in the network have increased rates of receiving antidementia drug treatments. These
findings suggest that dementia networks focusing on medical treatment should support diagnostic procedures and
incorporate physician specialists.
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Background
According to Prince et al. [1], it was estimated that 35.6
million people worldwide were suffering from dementia in
2010. In Germany approximately 1.5 million people are af-
fected by dementia [2]. Dementia is one of the most chal-
lenging global problems, especially for aging societies such
as the one in Germany. In Germany, the appropriate treat-
ment and care of people with dementia (PWD) has been
declared a public health priority. However, appropriate
PWD treatment requires a specialised mental health care
structure [3]. Among professionals, there is agreement
about the advantages of an integrated multi-modal care
approach to address the specific needs of dementia care
[4–6]. Dementia networks (DN) in Germany may be con-
sidered as a model for such integrated care. DN have
shown potential on relevant outcomes such as pharmaco-
logical dementia treatment [7]. Even though DN are
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composed quite differently, they share a common goal:
providing adequate treatment to their users. Such care in-
cludes early diagnosis, integrated treatment, reduction of
caregiver burden, and the provision and dissemination of
information concerning dementia disease [8]. Thus, DN
address the transnational health policies of the European
Union Council and are an important setting for dementia
care [9]. To better understand DN a typical example is as
follows:
The network is built by general practitioners and spe-
cialized neurologist/ psychiatrist in residency, hospitals,
medical and social institutions. The network provides an
interdisciplinary, cooperative model incorporating vari-
ous medical care disciplines. The DN addresses two
main goals: first, an early and differential formal diagno-
sis and second, a person-centered and comprehensive
therapy according to the progression of the syndrome.
To achieve these goals, DN established a specific demen-
tia care pathway.
Antidementia drugs are currently considered the primary
medical treatment for dementia [10]. The national guidelines
in Germany recommend substances that include acetyl-
cholinesterase inhibitors and the N-Methyl-D-Aspartate an-
tagonist (memantine) [10, 11]. Donepezil, galantamine
and rivastigmine are approved for the treatment of mild
to moderate Alzheimer’s dementia and memantine for
the treatment of moderate to severe Alzheimer’s dementia
and although the effects are inconsistent. Ginkgo is ap-
proved but not recommended in the national guidelines
for the treatment of dementia [10, 12]. Rivastigmine is the
approved treatment for mild to moderate dementia in
Parkinson’s disease.
Van den Bussche et al. [13] analysed antidementia pre-
scription rates in a nationwide statutory health insurance
company study of 1,848 PWD and found that 27 % of the
group had at least one antidementia prescription. Further-
more, PWD with a formal diagnosis of Alzheimer (35 %)
received more prescriptions than those with an unspecific
type of diagnosis (7 %) or with a diagnosis of vascular de-
mentia (7 %). If PWD were treated by a specialist, they re-
ceived more antidementia prescriptions compared to
those treated by a principal care physician (PCP) [13]. In
Germany, PCP are considered as the gateway and point of
entry to a medical treatment. They are responsible for
treatment in general. In specialised settings such as
German nursing homes, Huber et al. [14] found that
15.2 % of 8,017 PWD were taking at least one antidemen-
tia drug. Furthermore, in a statutory health insurance
study based on general population data, Hoffmann et al.
[15] found that age is a predictor for increased rates of
antidementia drug treatment. In a register based study,
Taipale et al. [16] observed that 84 % of the 6,858
community-dwelling PWD were being treated with at
least one antidementia drug. A study in France by
Tifratene et al. [17] showed that 76.9 % of the 26,809 indi-
viduals who were registered in the French National
Alzheimer’s Bank and had received a diagnosis were
treated with antidementia drugs.
However, little is known about treatment with antide-
mentia drugs in specialised settings such as DN. There-
fore, the objectives of the present analysis are to
describe antidementia drug treatment and to analyse the
factors that influence treatment in the specialised setting
of DN in Germany.
Methods
Sample and data collection
The analysis is based on cross-sectional data of the ongoing
study “Dementia Networks in Germany (DemNet-D)”.
DemNet-D was conducted to analyse structures, proce-
dures, and outcomes of DN in Germany using qualitative
and quantitative methods. Ethical approval was obtained
from the Committee of Ethics at the University of
Greifswald (register number BB 107/12). Thirteen DN
throughout Germany were included in the study. These
networks applied for funding to participate and were
chosen by the funding agency—the Federal Ministry of
Health (BMG). Inclusion criteria were (a) having been
previously evaluated and (b) being considered a sus-
tainable network. Currently the total number of DN in
Germany is unknown, however the funding opportunity
was made public and all existing DN in Germany were
eligible to participate.
For the analyses, we collected data from 560 pairs of
PWD and their caregivers. Inclusion criteria for each pair
were (a) being served by one of the 13 networks and (b) is-
suing of written informed consent by both the PWD and
the caregiver. Participants were randomly selected by the
DN according to these inclusion criteria during a timeframe
of 6 months. Data were collected through in-person inter-
views and paper questionnaires by trained interviewers.
The interviewer were employed by the DN, the professional
background was heterogeneous. All were experienced in
communicating and dealing with PWD and caregivers by
employment criteria. Specific qualification for conducting
the assessments was provided by two group trainings and a
written manual, both specifically designed for this study.
The interview period lasted from the 1st of February until
the end of September 2013, and recruitment was conducted
by regional DN staff. Except for the geriatric depression
scale (GDS) [18] all information was given by the inter-
viewed caregiver. Information of the GDS was based on the
answers given by the PWD.
Measures
The collected socio-demographic information included
gender, age, living situation and region. Living situation was
categorised as either (a) living alone in own household or
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(b) living together with others. Type of region was classified
as either urban/suburban or rural. Socio-economic status
(SES) was operationalized using the Scheuch-Winkler index
[19], a combination of household income, years of educa-
tion and profession and categorised as high, middle and
low SES. Information about comorbidity was collected
using a paper questionnaire. To identify which diseases
affect each PWD, participants were provided with a list of
the most common diseases in geriatrics (hypertension,
hyperlipidemia, adipositas, diabetes, coronary heart disease,
heart attack, cardiac insufficiency, stroke, asthma, chronic
bronchitis, renal insufficiency, hepatic insufficiency, enter-
itis, gastritis, stomach ulcer, duodenal ulcer, arthrosis, rheu-
matoide arthritis, osteoporosis, chronic back pain, cancer,
deafness, visual impairment) from that they could check
off. More specific and rare diseases could be indicated in
open text fields. Diagnoses were transferred into ICD 10
codes. Functional status was measured using the Instru-
mental Activities of Daily Living (IADL) score according to
Lawton and Brody [20]. This index ranges from 8 (no activ-
ity restrictions in daily living) to 0 (comprehensive activity
restrictions in daily living). Depression was measured using
the short-form geriatric depression scale (GDS) [18], with a
score greater than 5 indicating depression. The caregiver
was also asked about the presence of a diagnosis and the
type of the dementia from the PWD.
The DN was categorised into either (a) physician
associated networks, or networks led by a specialist
(neurologist/psychiatrist) or (b) others. The other net-
works where community oriented networks focused on
care providers. They aim to improve the management,
evaluation and service integration for PWD in the sec-
tor of nursing care providers. To assess drug treatment,
drugs were recorded by name, dose, and frequency of
use. The following drugs were considered: donepezil
(N06AD02), rivastigmine (N06AD03), galantamine
(N06AD04), memantine (N06AX01), and ginkgo biloba
(N06DP01) [21].
We assessed the daily target dose according to the
national guidelines and recommendations for acetyl-
cholinesterase inhibitors and N-Methyl-D-Aspartate
[10]. The daily dosage was categorised as “target dose
as recommended” or “others,” including: 20 mg/d for
memantine, 10 mg/d for donepezil, 6–12 mg/d (9.5 mg/d –
transdermal therapeutic system) for rivastigmine, and
16–24 mg/d for galantamine [10]. We defined the
period of intake as the beginning of the antidementia
drug treatment until time of the interview.
Statistical analysis
We used descriptive statistics to summarize the demo-
graphic characteristics of the sample. To evaluate the as-
sociations of the prescription of antidementia drugs, we
performed multiple logistic regression analyses with the
prescription of the antidementia drug as the outcome
variable. The model was adjusted for age, sex, comorbid-
ities, functional status, depression, living situation (di-
chotomous: alone vs. not alone), diagnosis of dementia,
and the network association (medical vs. others). Add-
itionally, we accounted for the correlated nature of our
data because observations from PWD in the same net-
work were unlikely to be independent. Thus, we in-
cluded the network as a random effect in our model.
Prior to fitting the final regression model, we checked
for non-linear associations of the covariates with the
outcome by using the multivariate fractional polynomial
approach [22]. As expected, the association with age
showed a departure from linearity and age was therefore
categorised into four age groups using the quartiles of
the birth years as cut-off values (group 1: 1910–1927;
group 2: 1928–1932; group 3: 1933–1937; group 4:
1938–1969). For graphical analysis, we modelled age
with restricted cubic splines using three equally spaced
knots [23].
We listed the name of the drug and the prevalence of
usage by the PWD in the cohort. To show the drug dos-
age, we used the mean frequencies of the intake per day
and the dose of each antidementia drug in the cohort.
Two-sided p-values were calculated with a two-sided
significance level (p-value = 0.05). The statistical package
used for the analysis was STATA 11 (StataCorp LP,
Texas, USA).
Results
Descriptive data are presented in Table 1. The majority
of the participants were female (58.3 %). Only a low per-
centage of the PWD were not diagnosed with any type
of dementia or did not know (n = 48, 8.7 %). Overall,
18.1 % lived in rural regions, and 21.3 % stated that they
were living alone in their own household. The mean
number of comorbidities was 3.9. Common diseases that
were found in the study population were cardiovascular
(n = 420, 80.6 %), with a total of 755 ICD 10 diagnoses,
and orthopaedic (n = 301, 57.7 %), with a total of 441
ICD 10 diagnoses. Most of the participants were
assigned to a low (60.6 %) or middle (29.6 %) socioeco-
nomic status. In addition, 39.9 % (n = 196) showed de-
pressive symptoms according to the GDS.
Antidementia drug treatment
Overall, half of the participants were treated with antide-
mentia drugs (52.3 %, n = 283). Of these drugs, the most
widely used were the acetylcholinesterase inhibitors
(62.9 %, n = 168). Memantine was used by 37.1 % of the
PWD (n = 99). Overall, 6.7 % (n = 19) of those PWD who
were using antidementia drug therapy were treated with
two antidementia drugs. The most common combinations
were memantine/donepezil (n = 9) and rivastigmine/
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memantine (n = 5). In the study sample, 5.1 % (n = 29) of
the PWD used ginkgo biloba substances: 13 PWD used an
antidementia drug plus ginkgo biloba, and 15 PWD used
the ginkgo biloba extract alone. In addition, 9.3 % (n = 25)
of the PWD were treated with dosages other than the rec-
ommended target dosage according to the national guide-
lines [10] (Table 2).
Associations between socio-demographic and clinical
variables and the use of anti-dementia drug treatment
The regression model indicates that age, diagnosis, pres-
ence of a physician specialist in the network, number of
comorbidities and living situation are associated with
antidementia drug treatment. We found nonlinear asso-
ciations for age. Although the second age group showed
an odds ratio of 2.97 (p = 0.002) for antidementia treat-
ment compared with the oldest age group, the third and
the fourth age groups were not significantly different
from the oldest age group. This result is reflected in
Fig. 1, where the rate of antidementia drug treatment
follows a reversed u-shaped curve.
We also found a significant association with the pres-
ence of a dementia diagnosis (p = <0.001) and antide-
mentia treatment. The odds ratios for antidementia
treatment of PWD with diagnosed dementia were 16.81
compared to the group without a formal diagnose. The
largest antidementia drug treated group were PWD with
a diagnosis of Alzheimer’s disease (73 %, n = 152). We
Table 1 Descriptive analysis of the study sample
n* Variable
Age 555 years m (SD) 79,7 (8.4)
Gender 557 female % 325 (58.3)
Social Status 409 lower class % 248 (60.6)
middle class % 121 (29.6)
higher class % 40 (9.8)
Formal Diagnosis of Dementia 551 yes % 503 (91.3)
Type of Dementia 476
Alzheimer Dementia 211 yes % 44.3
Vascular Dementia 92 yes % 19.3
Unspecific 155 yes % 32.6
Others 18 yes % 3.8
Antidementia Treatment 541 yes % 283 (52.3)
Combination Therapy 283 yes % 19 (6.7)
Region 553 rural % 100 (18.1)
Living Situation 558 alone in own
household
% 119 (21.3)
Functional Status 511 IADL score median (range) 2 (0–8)
Depression 491 GDS median (range) 4 (0–15)
Comorbidities 521 number of
morbidity’s
mean (SD) 3.9 (2.1)
Consultation Specialists 532 treated by neurologist/psychiatrists % 395 (74.2)
533 visits during the last 6 months mean (SD) 2.3 (1.5)
Consultation PCP 550 treated by primary care physicians (PCP) % 513 (93.3)
530 visits during the last 6 months mean (SD) 3.9 (2.5)
*cases with missing values on the respective variable were excluded from calculation of frequencies and means; PCP included general practitioners and internists
in primary practice; IADL instrumental activities of daily living (0- no function, 8- complete function), GDS geriatric depression scale short- form (0- no depression,
5- suspicion of depression), Type of dementia – Others (Lewy-Body-Dementia, Korsakov, Frontotemporal dementia)
Table 2 Antidementia drugs in the sample




Antidementia n = 267 (%)
1. Memantine 99 (37.1) 25.25 (25.1) / n = 77 20 mg/d (90)
2. Donepezil 85 (31.8) 24.72 (22.5) / n = 65 10 mg/d (79)
3. Rivastigmine 52 (19.5) 21.33 (19.9) / n = 40 9.5 mg/d (35)
4. Galantamine 31 (11.6) 38.14 (26.2) / n = 21 16 mg/d (29)
Ginkgo biloba
1. Ginkgo n = 29 (5.1) 24.24 (26.1) / n = 17 120 mg/d (23)
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found a difference of 32 % lower rates of antidementia
treatment for the group of unspecified dementia diagno-
sis (41 %, n = 62). The physician associated network was
a significant positive factor in influencing treatment with
antidementia drugs (OR 3.69, p < 0.001). A higher num-
ber of comorbidities was associated with lower rates of
antidementia drug treatment (OR 0.87, p = 0.039). An-
other significant factor in the regression model was the
individual living situation. PWD who lived alone in their
own households had a lower chance of using antidemen-
tia drug treatment (OR 0.51, p = 0.032) as compared to
those living together with others (Table 3).
Discussion
Approximately half of the PWD (52 %) served in DN in
Germany received an antidementia drug treatment.
Koehler et al. [7] reported comparable numbers in their
evaluation of a rural dementia network, in which
50.5 % of PWD received antidementia drugs. These
numbers are higher than those estimated based on the
national health insurance data. Van den Bussche et al.
[13] reported 27 % for PWD in primary care, and Hu-
ber et al. [24] found a rate of only 15.2 % for nursing
home residents in Germany. Other published health
claims data show that 28 % of all PWD in Germany are
treated with antidementia drugs (estimated from at
least 1 million PWD) [25]. Utilisation rates of antide-
mentia drugs are therefore 24-37 % higher in our sam-
ple of PWD in DN compared to population based data
in Germany. Half of the participants (48 %) were not
treated with antidementia drugs. Reasons for the non-
antidementia treatment were not assessed but could be
for example a missing indication (like for unspecific
types or Lewy body and vascular forms of dementia).
Antidementia drug treatment for these forms is only
off-label (unspecific type) use or not-recommended. In
our sample, 72 % of patients with Alzheimer’s disease
were treated with antidementia drugs. Therefore PWD
with Alzheimer type of dementia clearly receive higher
numbers of antidementia drug treatment. Higher pro-
portions with Alzheimer form were also found by Tifratene
et al. [16]. Besides a lack of indication there also might
be a group of PWD where the antidementia drug treat-
ment has been already terminated. This could be re-
lated to late stages of dementia or the will of patients.
However, unfortunately any information about the non-
treatment is lacking. The responsible physician may
provide additional information to assess the non-
treatment in the sample. Further studies need to collect
more information about the group of PWD not treated
with antidementia drugs in DN.
In the group of PWD who received antidementia
drugs, 6.7 % took combined antidementia drug therapy
with two substances. Combination therapy has shown
potential in delaying the deterioration of functional
abilities in people with dementia [26]. Lopez et al. [27]
found that users of combination therapy comprised
14.9 % of their sample. Similar percentages were found
by Tifratene et al. [17] who reported 14.4 % of users of
combination therapy in their nationwide sample. This
finding is different from the results of our analysis,
which showed less utilisation of combined antidementia
drug treatments. However, this lower percentage may
be related to the clinical guidelines in Germany, which
describe a combination therapy only as an off-label
prescription [10]. In addition, only 5 % of the PWD
used ginkgo biloba drugs. This low percentage could be




OR 95 % CI p-value
Gender (fem.) 0.915 0.550 1.521 0.733
Formal diagnosis 16.813 5.228 54.066 <0.001
Age (category)
reference group: 1910-1927
2 (1928–1932) 2.974 1.503 5.883 0.002
3 (1933–1937) 1.771 0.884 3.549 0.107
4 (1938–1969) 0.962 0.467 1.982 0.917
Living alone 0.510 0.275 0.945 0.032
Comorbidities 0.879 0.778 0.993 0.039
Depression 0.989 0.917 1.067 0.789
Functional Status 1.065 0.920 1.233 0.393
Physician associated 3.692 1.808 7.539 <0.001
Comorbidity; score of morbidities exclusive dementia disease, functional sta.; IADL
instrumental activities of daily living (0- no function, 8- complete function),
depression; geriatric depression scale short- form (0- no depression, 5- suspicion
of depression)
Fig. 1 Proportion of antidementia treatment by year of birth
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explained by the lack of international reviews that demon-
strate the advantages of using ginkgo biloba for the treat-
ment of dementia. Ginkgo biloba is not recommended by
the pertinent national guidelines, though prescription rates
have been found to be related to the physician’s specialisa-
tion [28]. In the observational study of Jeschke et al. [28],
67.6 % of the 577 PWD were treated with ginkgo biloba by
a group of 22 physicians who specialise in complementary
and alternative medicine. Given the low percentage of users
of ginkgo biloba treatment in our study, it appears that
health care providers within DN are following the national
guidelines concerning antidementia drug treatment.
The treatment of dementia with antidementia drugs
in PWD served by DN is associated with age, comor-
bidities, diagnosis, associated specialists in the network,
number of comorbidities, and living situation. Utilisa-
tion of an antidementia drug treatment by PWD in-
creased with age and decreased beyond the age of 82.
This finding is contrary to the results of Hoffmann
et al. who found that utilisation of antidementia drug
treatment increased with age in the German population
[15]. The authors evaluated the prescription rates of
people older than 65 years and a diagnosis of dementia
in data from a health insurance company in Germany.
Our results suggest that reasons for the absence of
antidementia drug treatment can be diverse, though
health care providers should be aware of general treat-
ment gaps for elderly PWD. Hoffmann et al. showed
that the clinical condition is related to the prescription
rates of acetylcholinesterase inhibitors [29]. They found
a higher number of symptoms related to decreasing
rates of antidementia drug treatment [29]. We also
found that the number of comorbidities was associated
with lower odds ratios for the prescription of antide-
mentia drugs in our sample, but with a nonlinear asso-
ciation for increasing age. These data indicate that the
number of comorbidities, clinical conditions, and age
of the PWD are associated with lower rates of antide-
mentia drug therapy. Prescriptions and medication ad-
herence within a multi-morbidity population such as
found in DN are dependent on organisational changes
such as providing case management or enhancing
multidisciplinary team work [30]. In our sample, we
found that PWD who are living alone had reduced rates
of antidementia drug treatment overall. This finding
may be related to lower adherence or consultations
with physicians. In a nationwide sample of 7,570 PWD
living at home, Johnell et al. also found reduced rates
for antidementia drug treatment [31]. An association
between social environment and dementia care was
also confirmed by Lehmann et al. in their sample of
349 community-dwelling PWD. Primary care physicians
were less likely to detect dementia within subjects
living alone [32]. An association between social
environment and cognition has also been described.
Fratiglioni et al. showed that number of contacts and
quality of relationships are associated with cognition in
PWD [33]. In addition to our results, these studies indicate
the importance of the living situation of the PWD, calling
for an awareness of PWD living alone. Health care net-
works like DN are more likely to integrate PWD living
alone, as they integrate various health care providers who
are aware of specific dementia health care concepts com-
pared to a fragmented health care landscape [8].
The most relevant determinant for drug therapy was
the presence of a dementia diagnosis. Although only
8.7 % of the PWD reported that they had not received a
diagnosis, this factor was highly significant for antide-
mentia drug treatment. This finding underscores the
strategy of the World Health Organization, which pro-
motes diagnosis as a key element for dementia care [6].
Without a specific diagnosis, PWD were also treated
differently. Seventy-three percent of patients with
Alzheimer’s disease received antidementia drugs, whereas
only 41 % of patients with an unspecific dementia diag-
nosis were treated. However, approximately 9 % of the
PWD stated a lack of a formal diagnose in their case. It
is unclear if this group did not receive a formal diag-
nose or if they did not know. Furthermore, the specific
diagnosis could differ between self-report and medical
record. A validation of the formal diagnosis with the in-
formation documented by the responsible physician
would provide additional information to this issue.
However, this correlation was also confirmed by Hoffmann
et al. [15]. The authors found that the chance for antide-
mentia prescriptions was lower with the diagnosis of vascu-
lar dementia and higher with the diagnosis of Alzheimer
disease [15].
In our data, we found that 11 % (n = 29) of the cho-
linesterase inhibitors and memantine was inconsistent
with national guideline recommendations with respect
to daily dose. Tifratene et al. found 20.7 % of antide-
mentia pharmacotherapy to be non-compliant with na-
tional guidelines [17]. Therefore, discrepancies between
guideline recommendations and utilisation data are com-
mon, based on the work of Tifratene et al. However, our
definition of target dose would not detect non-compliance.
We found no associations between function and signs of
depression in our sample. Hoffmann et al. found relation-
ships between care dependency status and lower rates of
antidementia drug treatment [29]. The authors analysed
cholinesterase inhibitor treatment without the drug class of
Methyl-D-Aspartate antagonist (memantine). This associ-
ation might be lower if memantine had been included.
However, insignificant associations between function limita-
tions, signs of depression and pharmaceutical antidementia
drug treatment may be related to the integrated care struc-
ture of DN. Overall, the antidementia drug treatment
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figures of DN are clearly higher than the figures that have
been published in Germany thus far.
Conclusion
PWD using DN in Germany received antidementia drugs
more frequently than PWD in primary or nursing home
care situations. In these networks, factors that most influ-
enced using antidementia drug treatments were formal
diagnosis of dementia, presence of a physician in the net-
work, number of comorbidities, living situation, and age.
Based on these findings, further interventions should con-
sider the effects of PWD living alone, prevent discrimin-
ation of the elderly and provide low threshold diagnostic
services. Involvement of specialised physicians in DN would
likely help to improve rates of antidementia drug treatment.
Gaps between guideline recommendations and antidemen-
tia drug treatment should be examined more closely to
eliminate risks of ineffective treatments and potential nega-
tive side effects.
Limitations
The study has limitations that decrease the generalisabil-
ity. Results are based on the self-report only. Data could
not be verified with the PWDs primary physician or with
health insurance information. Future research should
collect additional information from the health insurance
company and/ or the responsible physician. Further-
more, there could be a selection bias in the DN under
examination. However, participation was open to all DN
in Germany.
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